Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID | D0A2SK | ||||
| Former ID | DNC013505 | ||||
| Drug Name | (Z)-1-(pyridazin-3-yl)octadec-9-en-1-one | ||||
| Drug Type | Small molecular drug | ||||
| Indication | Discovery agent | Investigative | [529193] | ||
| Formula | C22H36N2O | ||||
| Canonical SMILES | CCCCCCCCC=CCCCCCCCC(=O)C1=NN=CC=C1 | ||||
| InChI | 1S/C22H36N2O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-22(25)21-18-17-20-23-24-21/h9-10,17-18,20H,2-8,11-16,19H2,1H3/b10-9- | ||||
| InChIKey | REQRZXMTFPJHJQ-KTKRTIGZSA-N | ||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Fatty-acid amide hydrolase | Target Info | Inhibitor | [529193] | |
| BioCyc Pathway | Anandamide degradation | ||||
| KEGG Pathway | Retrograde endocannabinoid signaling | ||||
| PANTHER Pathway | Anandamide degradation | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.
